Leulan Bioscience Inc.

Diagnostic service providing AT-HOME blood collection to monitor immunosuppressants and biomarker for kidney transplant patients.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Founded January 2019
  • Employees 1
  • Incorporation Type C-corp
  • Website leulan.com

Company Summary

Round NOT closed. Please review.

To improve kidney transplant recipients (KTRs) care, Leulan is developing a novel at-home blood sample collection method and creating a diagnostic service that is safe and convenient. Due to the current pandemic, KTRs have a higher risk of infection from coronaviruses. Leulan will provide the blood sample collection kit and let KTRs collect at their own home for monitoring of immunosuppressants and biomarkers.

Team

  • Ying Qu
    Founder, CEO/CSO

    Dr. Qu received BS and MS in Chemistry, Ph.D. in Neuroscience and did a postdoc at NIH. Dr. Qu had experience in leading a small R&D team for developing clinical diagnostic products. Her team successfully launched the clinical diagnostic products. one of the products that used a VAMS as a sample collection method. These are commercial-stage diagnostic products that provide physicians with clinical tools to address the significant unmet need.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free